Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection

被引:211
作者
Jansen, Flip H. [1 ]
van Schaik, Ron H. N. [2 ]
Kurstjens, Joep [2 ]
Horninger, Wolfgang [3 ]
Klocker, Helmut [3 ]
Bektic, Jasmin [3 ]
Wildhagen, Mark F.
Roobol, Monique J.
Bangma, Chris H.
Bartsch, Georg [3 ]
机构
[1] Erasmus MC, Dept Urol, Josephine Nefkens Inst, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Clin Chem, NL-3000 CA Rotterdam, Netherlands
[3] Innsbruck Med Univ, Dept Urol, Innsbruck, Austria
关键词
Prostate cancer screening; PSA isoforms; p2PSA; BPHA; TRANSITION ZONE; PRECURSOR FORM; MOLECULAR-FORM; SERUM; BPSA; MEN; ROUNDS; ERSPC;
D O I
10.1016/j.eururo.2010.02.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Novel markers for prostate cancer (PCa) detection are needed. Total prostate-specific antigen (tPSA) and percent free prostate-specific antigen (%fPSA = tPSA/fPSA) lack diagnostic specificity. Objective: To evaluate the use of prostate-specific antigen (PSA) isoforms p2PSA and benign prostatic hyperplasia-associated PSA (BPHA). Design, setting, and participants: Our study included 405 serum samples from the Rotterdam arm of the European Randomised Study of Screening for Prostate Cancer and 351 samples from the Urology Department of Innsbruck Medical University. Measurements: BPHA, tPSA, fPSA, and p2PSA levels were measured by Beckman-Coulter Access Immunoassay. In addition, the Beckman Coulter Prostate Health Index was calculated: phi = (p2PSA/fPSA) x root(tPSA). Results and limitations: The p2PSA and phi levels differed significantly between men with and without PCa. No difference in BPHA levels was observed. The highest PCa predictive value in both cohorts was achieved by phi with areas under the curve (AUCs) of 0.750 and 0.709, a significant increase compared to tPSA (AUC: 0.585 and 0.534) and %fPSA (AUC: 0.675 and 0.576). Also, %p2PSA (p2PSA/fPSA) showed significantly higher AUCs compared to tPSA and %fPSA (AUC: 0.716 and 0.695, respectively). At 95% and 90% sensitivity, the specificities of phi were 23% and 31% compared to 10% and 8% for tPSA, respectively. In both cohorts, multivariate analysis showed a significant increase in PCa predictive value after addition of p2PSA to a model consisting of tPSA and fPSA (increase in AUC from 0.675 to 0.755 and from 0.581 to 0.697, respectively). Additionally, the specificity at 95% sensitivity increased from 8% to 24% and 7% to 23%, respectively. Furthermore, %p2PSA, phi, and the model consisting of tPSA and fPSA with or without the addition of p2PSA missed the least of the tumours with a biopsy or pathologic Gleason score >= 7 at 95% and 90% sensitivity. Conclusions: This study shows significant increases in PCa predictive value and specificity of phi and %p2PSA compared to tPSA and %fPSA. p2PSA has limited additional value in identifying aggressive PCa (Gleason score >= 7). (C) 2010 European Association of Urology. Published by Elsevier B. V. All rights reserved.
引用
收藏
页码:921 / 927
页数:7
相关论文
共 23 条
  • [1] Tyrol Prostate Cancer Demonstration Project: Early detection, treatment, outcome, incidence and mortality
    Bartsch, Georg
    Horninger, Wolfgang
    Klocker, Helmut
    Pelzer, Alexandre
    Bektic, Jasmin
    Oberaigner, Wilhelm
    Schennach, Harald
    Schaefer, Georg
    Frauscher, Ferdinand
    Boniol, Mathieu
    Severi, Gianluca
    Robertson, Chris
    Boyle, Peter
    [J]. BJU INTERNATIONAL, 2008, 101 (07) : 809 - 816
  • [2] Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk
    Berger, AP
    Deibl, M
    Steiner, H
    Bektic, J
    Pelzer, A
    Spranger, R
    Klocker, H
    Bartsch, G
    Horninger, W
    [J]. PROSTATE, 2005, 64 (03) : 240 - 245
  • [3] Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer
    Canto, EI
    Singh, H
    Shariat, SF
    Lamb, DJ
    Mikolajczyk, SD
    Linton, HJ
    Rittenhouse, HG
    Kadmon, D
    Miles, BJ
    Slawin, KM
    [J]. UROLOGY, 2004, 63 (05) : 905 - 910
  • [4] Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml
    Catalona, WJ
    Bartsch, G
    Rittenhouse, HG
    Evans, CL
    Linton, HJ
    Amirkhan, A
    Horninger, W
    Klocker, H
    Mikolajczyk, SD
    [J]. JOURNAL OF UROLOGY, 2003, 170 (06) : 2181 - 2185
  • [5] Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen
    Catalona, WJ
    Bartsch, G
    Rittenhouse, HG
    Evans, CL
    Linton, HJ
    Horninger, W
    Klocker, H
    Mikolajczyk, SD
    [J]. JOURNAL OF UROLOGY, 2004, 171 (06) : 2239 - 2244
  • [6] Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer
    De Vries, SH
    Raaijmakers, R
    Blijenberg, BG
    Mikolajczyk, SD
    Rittenhouse, HG
    Schröder, FH
    [J]. UROLOGY, 2005, 65 (05) : 926 - 930
  • [7] COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH
    DELONG, ER
    DELONG, DM
    CLARKEPEARSON, DI
    [J]. BIOMETRICS, 1988, 44 (03) : 837 - 845
  • [8] Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma
    Hugosson, J
    Aus, G
    Lilja, H
    Lodding, P
    Pihl, CG
    [J]. CANCER, 2004, 100 (07) : 1397 - 1405
  • [9] Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease
    Linton, HJ
    Marks, LS
    Millar, LS
    Knott, CL
    Rittenhouse, HG
    Mikolajczyk, SD
    [J]. CLINICAL CHEMISTRY, 2003, 49 (02) : 253 - 259
  • [10] Mikolajczyk SD, 2000, PROSTATE, V45, P271